Quality of Life, Clinical Outcomes and Safety of Early Prophylactic Levothyroxine Administration in Patients With Graves' Hyperthyroidism Undergoing Radioiodine Therapy: A Randomized Controlled Study | oneGRAVESvoice

welcome to oneGRAVESvoice

- a positively charged Graves' disease and thyroid eye disease community.
  • join today!
Scientific Articles

Quality of Life, Clinical Outcomes and Safety of Early Prophylactic Levothyroxine Administration in Patients With Graves’ Hyperthyroidism Undergoing Radioiodine Therapy: A Randomized Controlled Study

key information

source: European Journal of Endocrinology / European Federation of Endocrine Societies

year: 2016

authors: Taïeb D, Bournaud C, Eberle MC, Catargi B, Schvartz C, Cavarec MB, Faugeron I, Toubert ME, Benisvy D, Archange C, Mundler O, Caron P, Abdullah AE, Baumstarck K

summary/abstract:

Objective:
While radioiodine therapy is commonly used for treating Graves’ disease, a prolonged and clinical hypothyroidism may result in disabling symptoms leading to deterioration of quality of life (QoL) of patients. Introducing levothyroxine (LT4) treatment in the early post-therapeutic period may be an interesting approach to limit this phenomenon.

Methods:
A multicenter, prospective, open-label randomized controlled trial enrolled 94 patients with Graves’ hyperthyroidism randomly assigned to the experimental group (n=46) (group A: early prophylactic LT4 treatment) or the control group (n=48) (group B: standard follow-up). The primary endpoint was the 6-month QoL. The secondary endpoints were other QoL scores such as Graves’ ophthalmopathy (GO) outcomes, thyroid function tests and safety.

Results:
The primary endpoint at 6 months was achieved: the mental composite score (MCS) of Short Form 36 (SF-36) was significantly higher in group A compared to group B (P=0.009). Four other dimension scores of the SF-36 and four dimension scores of the thyroid-specific patient-reported outcome (ThyPRO) significantly differed between the two groups, indicating better QoL in group A. After adjustment for variables, the early LT4 administration strategy was found as an independent factor for only two scores of SF-36: the MCS and the general health (GH) score. There were no differences in GO, final thyroid status and changes in the anti-TSH receptor antibodies (TRAbs) levels between the two groups. No adverse cardiovascular event was reported.

Conclusion:
Early LT4 administration post-radioactive iodine (RAI) could represent a safe potential benefit for patients with regard to QoL. The optimal strategy taking into account administered RAI activities and LT4 treatment dosage and timing remains to be determined.

organization: La Timone University Hospital, France; Aix-Marseille University, France; University Hospital of Bordeaux, France; Hospices Civils de Lyon, France; Brest University Hospital, France; Saint-Antoine Hospital, France; Saint-Louis Hospital, France; Toulouse University Hospital, France; Lapeyronie University Hospital, France; Godinot Institute, France

DOI: 10.1530/EJE-15-1099

full text source
Font Resize

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close